129 related articles for article (PubMed ID: 22702358)
1. Urine epigenomics: a promising path for bladder cancer diagnostics.
Sánchez-Carbayo M
Expert Rev Mol Diagn; 2012 Jun; 12(5):429-32. PubMed ID: 22702358
[No Abstract] [Full Text] [Related]
2. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer.
Hanke M; Hoefig K; Merz H; Feller AC; Kausch I; Jocham D; Warnecke JM; Sczakiel G
Urol Oncol; 2010; 28(6):655-61. PubMed ID: 19375957
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
4. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer.
Yu J; Zhu T; Wang Z; Zhang H; Qian Z; Xu H; Gao B; Wang W; Gu L; Meng J; Wang J; Feng X; Li Y; Yao X; Zhu J
Clin Cancer Res; 2007 Dec; 13(24):7296-304. PubMed ID: 18094410
[TBL] [Abstract][Full Text] [Related]
5. Epigenetics application in the diagnosis and treatment of bladder cancer.
Harb-de la Rosa A; Acker M; Kumar RA; Manoharan M
Can J Urol; 2015 Oct; 22(5):7947-51. PubMed ID: 26432963
[TBL] [Abstract][Full Text] [Related]
6. Moving forward in bladder cancer detection and diagnosis: the role of epigenetic biomarkers.
Oliveira AI; Jerónimo C; Henrique R
Expert Rev Mol Diagn; 2012 Nov; 12(8):871-8. PubMed ID: 23249204
[TBL] [Abstract][Full Text] [Related]
7. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples.
Costa VL; Henrique R; Danielsen SA; Duarte-Pereira S; Eknaes M; Skotheim RI; Rodrigues A; Magalhães JS; Oliveira J; Lothe RA; Teixeira MR; Jerónimo C; Lind GE
Clin Cancer Res; 2010 Dec; 16(23):5842-51. PubMed ID: 20975101
[TBL] [Abstract][Full Text] [Related]
8. miRNA panels as biomarkers for bladder cancer.
Tölle A; Ratert N; Jung K
Biomark Med; 2014; 8(5):733-46. PubMed ID: 25123040
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic biomarkers in urothelial bladder cancer.
Kim WJ; Kim YJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
[TBL] [Abstract][Full Text] [Related]
10. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
Urakami S; Shiina H; Enokida H; Kawakami T; Kawamoto K; Hirata H; Tanaka Y; Kikuno N; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2109-16. PubMed ID: 16609023
[TBL] [Abstract][Full Text] [Related]
11. Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine.
Lin HH; Ke HL; Huang SP; Wu WJ; Chen YK; Chang LL
Urol Oncol; 2010; 28(6):597-602. PubMed ID: 19181545
[TBL] [Abstract][Full Text] [Related]
12. Genetic and epigenetic biomarkers for early detection, therapeutic effectiveness and relapse monitoring in bladder cancer.
Dumache R; David D; Kaycsa A; Minciu R; Negru S; Puiu M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):163-7. PubMed ID: 21682190
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic markers as promising prognosticators for bladder cancer.
Kim YK; Kim WJ
Int J Urol; 2009 Jan; 16(1):17-22. PubMed ID: 18721202
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers.
Reinert T; Modin C; Castano FM; Lamy P; Wojdacz TK; Hansen LL; Wiuf C; Borre M; Dyrskjøt L; Orntoft TF
Clin Cancer Res; 2011 Sep; 17(17):5582-92. PubMed ID: 21788354
[TBL] [Abstract][Full Text] [Related]
15. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer.
Puerta-Gil P; García-Baquero R; Jia AY; Ocaña S; Alvarez-Múgica M; Alvarez-Ossorio JL; Cordon-Cardo C; Cava F; Sánchez-Carbayo M
Am J Pathol; 2012 May; 180(5):1808-15. PubMed ID: 22426337
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
[TBL] [Abstract][Full Text] [Related]
17. Urinary bladder tumor markers.
Lokeshwar VB; Selzer MG
Urol Oncol; 2006; 24(6):528-37. PubMed ID: 17138134
[TBL] [Abstract][Full Text] [Related]
18. Genetic and epigenetic aspects of bladder cancer.
Kim WJ; Quan C
J Cell Biochem; 2005 May; 95(1):24-33. PubMed ID: 15759278
[TBL] [Abstract][Full Text] [Related]
19. Aberrant methylation of RARbeta2 and APC genes in voided urine as molecular markers for early detection of bilharzial and nonbilharzial bladder cancer.
Eissa S; Swellam M; El-Khouly IM; Kassim SK; Shehata H; Mansour A; Esmat M; Nossier AI; Hamdy MA; Awad NM; El-Ahmady O
Cancer Epidemiol Biomarkers Prev; 2011 Aug; 20(8):1657-64. PubMed ID: 21680534
[TBL] [Abstract][Full Text] [Related]
20. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.
Friedrich MG; Weisenberger DJ; Cheng JC; Chandrasoma S; Siegmund KD; Gonzalgo ML; Toma MI; Huland H; Yoo C; Tsai YC; Nichols PW; Bochner BH; Jones PA; Liang G
Clin Cancer Res; 2004 Nov; 10(22):7457-65. PubMed ID: 15569975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
